Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), either used in monotherapy or in combination with chemotherapy. While some patients achieve durable responses, some will not get benefit from this treatment. Early identification of...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfranca, Yolanda Lage, García, María Eugenia Olmedo, Rueda, Ana Gómez, Ballesteros, Pablo Álvarez, Rodríguez, Diana Rosero, Velasco, Marisa Torres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181575/
https://www.ncbi.nlm.nih.gov/pubmed/35683629
http://dx.doi.org/10.3390/jcm11113245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181575/
https://www.ncbi.nlm.nih.gov/pubmed/35683629
http://dx.doi.org/10.3390/jcm11113245

Ejemplares similares